Bayer Will Stop Selling the Troubled Essure Birth Control Implants

July 20, 2018 – New York Times – Bayer announced on Friday that it would discontinue sales of its Essure birth control implant by the end of the year, bowing to a lengthy campaign by health advocates and thousands of women to get the device off the market.

The implant has had a troubled history. It has been the subject of an estimated 16,000 lawsuits or claims filed by women who reported severe injuries, including perforation of the uterus and the fallopian tubes. Several deaths, including of a few infants, have also been attributed to the device or to complications from it.

If these complaints were piling in, in their many, it is a surprise to people that it has continued to be an option of use for birth control. With the risk factors in place and the statistics showing these are higher than might have been previously expected, it is no wonder that these women have fiercely fought to get rid of the device and all the complications that come with it. Luckily for issues like this, the women suffering the consequences can find pain relief and recovery relief as well, in medications or even in some of the products found on https://vibescbd.co.uk/. Vibes CBD and many other companies like it tailor-make their products for these exact reasons, saving people’s lives when they thought there was nothing that could subside their pain! However, it doesn’t take away from the fact that this device was allowed to circulate even after a high amount of complaints came in especially as some of them regarded death! Luckily, something is finally being done about it, those who suffered can receive the support they need and women elsewhere can breathe a sigh of relief that it can no longer cause any more problems.

….

Madris Tomes, a former F.D.A. medical device official who runs a company that analyzes adverse event data, puts the figure closer to 30,000.

“With side effects ranging from hair loss and tooth loss to chronic pain, severe bleeding, miscarriages and even death, the benefit risk profile touted by Bayer simply didn’t jibe with the data that was pouring into the F.D.A. from both patients and physicians,” said Ms. Tomes, who has done pro bono work for an Essure patient advocacy group.

Read More…

Leave a Reply

Your email address will not be published. Required fields are marked *